Industry, CME, and OIG

WHILE THE OFFICE OF INSPECTOR General draft Compliance Program Guidance for Pharmaceutical Manufacturers, as published in early October, is directed specifically to the pharmaceutical industry, CME providers should take notice of several of its components. The Guidance addresses business policies and practices that could be in violation of federal statutes pertaining to kickbacks and false claims. In the mix is the possibility of fraud in industry-funded CME.

The OIG Guidance b

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish